Asthma preventive drugs market led by GlaxoSmithKline's Advair

The asthma preventive drugs market has been forecast to increase at a compound annual growth rate (CAGR) of 4.5% through to 2015, driven by the increasing incidence of asthma along with the increased focus on contract manufacturing outsourcing, according to a new report added to the offering of Companiesandmarkets.com

Asthma is a respiratory condition in which the airways become inflamed and constrict, usually in response to one or more environmental triggers. As a serious and potentially fatal condition if left untreated, asthma can be managed by avoiding triggers and with drug therapy.

Over 300 million people suffer from asthma. The global asthma drugs market has been forecast to increase at a compound annual growth rate (CAGR) of 5.7% over the next five years, and to increase from a market value of $15.3 billion recorded in 2012, to hit $20.2 billion by 2017.